A 20 year old man was referred to the eye clinic by his general practitioner with a four week history of a sore red left eye ( fig  1) . Treatment for conjunctivitis had not resulted in improvement, and he reported that his eye was increasingly painful. He had experienced repeated nose bleeds over the past three months, together with constant left sided nasal stuffiness. He had recently felt generally unwell and had lost 4 kg. On examination, his visual acuity was 6/9 in both eyes. His vital signs were stable, but urinalysis showed blood+++ and protein+. 
Short answer
The abnormality is in the sclera-the tough white outer coat of the globe. A large area of necrotic sclera can be seen extending around the superonasal side of the cornea.
Long answer
The abnormality is in the sclera-the tough white outer coat of the globe. A large area of necrotic sclera can be seen extending around the superonasal side of the cornea. Non-necrotising scleritis presents as a red sore eye, but the white avascular area of sclera seen here is indicative of necrotising disease.
What is the most likely underlying diagnosis given his extraocular symptoms? Short answer
Necrotising scleritis can be associated with several connective tissue disorders, the most common being Wegener's granulomatosis. The combination of necrotising scleritis, upper airway symptoms, and constitutional symptoms strongly suggest this as the diagnosis.
Long answer
Necrotising scleritis is associated with a medical disorder in 39-50% of cases, particularly connective tissue disease or systemic vasculitis. 
The diagnosis of necrotising scleritis is clinical, but because it is often associated with systemic disease a thorough investigation is essential. Patients should be investigated with urine dipstick for blood and protein, as well as serum rheumatoid factor, antinuclear antibodies, and ANCAs. White cell count, C reactive protein concentration, and erythrocyte sedimentation rate are useful to look for evidence of systemic inflammation.
If Wegener's granulomatosis is suspected, it is important to exclude serious renal involvement urgently. Radiographic assessment of the respiratory system and evaluation for renal disease are indicated. The ANCA test is usually positive in systemic Wegener's disease but can be negative, particularly if disease is limited to the orbit. 4 ANCAs may be present in other conditions (such as ulcerative colitis, ankylosing spondylitis, and Churg-Strauss syndrome), and a negative ANCA test does not exclude a diagnosis of Wegener's granulomatosis. 4 Direct immunofluorescence can distinguish different patterns of ANCA staining, and cytoplasmic ANCA (cANCA) staining is classic, whereas perinuclear ANCA (pANCA) staining is more commonly a feature of microscopic polyangiitis. The demonstration of antiproteinase 3 antibodies on ELISA (enzyme linked immunosorbent assay) has a sensitivity of 91% and specificity of 99% for active Wegener's granulomatosis. 3 A biopsy showing granulomatous inflammation and necrotic vasculitis is the gold standard in disease diagnosis. This may be obtained from an affected organ, such as the skin (in patients with cutaneous vasculitis), kidney, lung, or orbit (in those with granulomatous orbital inflammation). Although biopsy findings are notoriously non-specific, renal biopsies may have a higher diagnostic yield when performed by a skilled clinician and reviewed by an experienced histopathologist.
The modified American College of Rheumatology criteria for the diagnosis of Wegener's granulomatosis (1990) stipulate that at least two of the following be present: nasal or oral inflammation, abnormal chest radiograph, active urine sediment (microhaematuria or red cell casts), and positive biopsy. Some have argued that a positive ANCA titre be included as a fifth criterion. 5 
What is the pathophysiology of this condition? Short answer
Wegener's granulomatosis is an autoimmune systemic vasculitis, which commonly affects small and medium sized vessels. The precise causes are not known, and it belongs to a larger group of vasculitides in which disease is strongly associated with ANCAs, including Churg-Strauss syndrome and microscopic polyangiitis.
Long answer
Wegener's granulomatosis is a rare disease. Its prevalence is 5-16 per 100 000 in northern Europe 6 and three per 100 000 in the United States. 7 The average age of onset is 40-55 years, but it may present at any age. There is no sex bias. The condition is more common in white people than in Afro-Caribbeans.
Wegener's granulomatosis is an autoimmune disease characterised by systemic vasculitis, which commonly affects small and medium sized vessels, as well as by granuloma formation. The precise causes are not known, 8 and it belongs to a larger group of vasculitides in which disease is strongly associated with ANCAs, including Churg-Strauss syndrome and microscopic polyangiitis.
ANCAs are present in 90-95% of patients with systemic Wegener's disease. 9 ANCAs directed against serum proteinase 3 lead to neutrophil activation, with resultant release of reactive oxygen species and proteolytic enzymes, which cause damage to the vascular endothelium and result in vasculitis. 10 Activation of the immune system leads to disease in small and medium sized vessels and causes multiorgan disease. The condition commonly affects the upper respiratory tract and lungs, as well as the kidneys, where rapidly progressive glomerulonephritis commonly leads to chronic renal failure if not treated quickly and aggressively. Wegener's granulomatosis can also cause painful swollen joints and skin nodules on the elbows; less commonly, it also affects the brain and peripheral nervous system, heart, and gastrointestinal tract. The varied and non-specific nature of the symptoms often leads to delayed diagnosis.
What treatment would you recommend and what is the prognosis? Short answer
Wegener's granulomatosis is life threatening and requires aggressive immunosuppression; cyclophosphamide has revolutionised the management of this previously fatal condition. Once the diagnosis is confirmed, start patients on intravenous infusions of cyclophosphamide and high dose oral prednisolone (1-2 mg/kg/day). Treatment of the underlying condition leads to rapid resolution of necrotising scleritis without the need for local treatment, unless the globe has already perforated, in which case emergency surgery may be needed. Most patients respond well to treatment, and survival is about 95% at five years and 80% at 10 years.
Long answer
Wegener's granulomatosis is life threatening and requires aggressive immunosuppression; cyclophosphamide has revolutionised the management of this previously fatal condition. 11 Once the diagnosis is confirmed, patients should be started on intravenous infusions of cyclophosphamide and high dose oral prednisolone (1-2 mg/kg/day). Treatment of the underlying condition leads to rapid resolution of necrotising scleritis without the need for local treatment, unless the globe has already perforated, in which case emergency surgery may be needed.
Patients treated with cyclophosphamide must be monitored for serious treatment related toxicity, including bone marrow suppression and haemorrhagic cystitis. 12 Once remission is induced, introduce less toxic drugs such as azathioprine or
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe methotrexate instead. 13 14 Taper steroids to 7.5 mg/day or less and continue treatment for at least one year. Plasmapheresis is effective in pulmonary haemorrhage secondary to Wegener's disease. 15 Newer biological agents have also been evaluated, and the RAVE (Rituximab in ANCA associated Vasculitis) study compared the ability of rituximab plus corticosteroids versus cyclophosphamide plus corticosteroids to induce remission in patients with severe systemic Wegener's disease. 16 Rituximab was as effective as cyclophosphamide in inducing remission but more effective in treating relapsing disease. Rituximab is also effective in the treatment of refractory ophthalmic disease. 17 Untreated, Wegener's granulomatosis is rapidly fatal as a result of renal failure and pulmonary haemorrhage, with a median survival of five months. The use of steroids helped increase average survival to eight months, but it was the use of cyclophosphamide in the 1970s that led to dramatic improvements in prognosis. These days, most patients respond well to treatment, and survival is about 95% at five years and 80% at 10 years. 11 18 Relapses are common and should be treated aggressively. Long term complications include chronic renal failure and hearing loss.
Patient outcome
Our patient was diagnosed with Wegener's granulomatosis. Pulmonary nodules were seen on chest radiography and he was positive for ANCAs on direct immunofluorescence and for antiproteinase 3 antibodies on ELISA.
He was started on 80 mg oral prednisolone daily; concurrent infusions of cyclophosphamide were arranged in conjunction with the renal physicians through our multidisciplinary vasculitis clinic, which includes renal doctors; ophthalmologists; and ear, nose, and throat surgeons.
His symptoms improved rapidly with treatment. His nose bleeds and nasal congestion improved, and he rapidly regained some weight and felt better systemically. The necrotising scleritis resolved without compromise to his vision (fig 2) . 
